#CureBronchoiectasis

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...

Is there a better thing for a physician scientist than to have an impact on our patients - to take a previously ignored and hopeless disease and make it treatable?
Kudos Prof Chalmers ! What an amazing achievment!!! also 👏🏼to all #Aspen investigators 👏🏼
#CureBronchoiectasis
#ScienceMatters